Enclomiphene Citrate Mechanism of Action: The Full Hormonal Pathway Explained

At a glance

• Drug class / oral selective estrogen receptor modulator (SERM) [1]
• Main action / blocks estrogen receptors in the pituitary [1]
• Hormone result / more LH and FSH released [1]
• Testicular effect / Leydig cells make more testosterone; Sertoli cells support sperm [1]
• Best-fit condition / secondary (hypogonadotropic) hypogonadism [1]
• Not expected to work in / primary hypogonadism (testicular failure) [1]
• Approval / not FDA-approved; EMA refused EnCyzix in 2018 [1][2]
• Half-life / about 10 hours; peak 2 to 3 hours [1]

What does enclomiphene do in the body?

Enclomiphene does not add testosterone. It lifts estrogen's suppression of the pituitary. Estrogen normally suppresses the pituitary-testis axis, and enclomiphene blocks estrogen receptors in the pituitary [1]. With that suppression reduced, the pituitary releases more LH and FSH [1]. LH then signals Leydig cells in the testes to make testosterone. FSH supports Sertoli cells, which are needed for sperm production [1]. The result is the body's own testosterone, not an external testosterone dose.

The phase 3 report describes this as restoration instead of replacement [3]. Enclomiphene is not a testosterone product, and its effect depends on a pituitary that can raise LH and FSH and on testes that can respond [1].

What happens to LH, FSH, and sperm?

In the phase 3 ZA-304 and ZA-305 studies, total testosterone rose in all treatment groups over 16 weeks [3]. LH and FSH rose with enclomiphene and fell with testosterone gel [3]. Sperm concentration stayed in the normal range on enclomiphene, while there was a marked reduction in spermatogenesis on testosterone gel [3]. That is the mechanistic contrast: exogenous testosterone suppresses LH and FSH; enclomiphene raises them.

The sperm effect is not absolute. In ZA-301, sperm concentration fell by 50% or more in 14.2% of men on enclomiphene versus 2.6% on placebo [4]. In ZA-302, the figures were 14.2% versus 4.3% [5]. So enclomiphene preserved sperm better than testosterone gel in these trials, but some men still had a large decline.

What did the phase 3 trials actually measure?

ZA-301 enrolled 151 overweight men aged 18 to 60 with acquired hypogonadotropic hypogonadism, morning testosterone under 300 ng/dL and normal sperm concentration; men received enclomiphene 12.5 mg or 25 mg daily or placebo for 12 weeks [4]. Among pooled enclomiphene patients, 78.8% reached an average 24-hour testosterone in the normal range of 300 to 1,040 ng/dL (95% CI 70.3 to 85.3, n=113) [4]. ZA-302 enrolled 181 men, and 81.3% of those on enclomiphene reached the normal range (95% CI 73.9 to 87.0, n=134) [5].

These trials measured hormones and sperm counts. Enclomiphene raised testosterone in these studies, but they did not establish whether symptoms improved [1].

How is enclomiphene different from clomiphene?

Clomiphene citrate is a mixture of two isomers: enclomiphene (trans) and zuclomiphene (cis) [1]. Per FDA, the USP monograph gives enclomiphene content of clomiphene as 50 to 70 percent [1]. They are related but not the same drug. Zuclomiphene is more estrogenic; enclomiphene is the more anti-estrogenic, pro-gonadotropic isomer [6]. The clomiphene label says zuclomiphene has a longer half-life than enclomiphene and that detectable levels persisted for longer than a month [7].

Clomiphene itself is FDA-approved only for ovulatory dysfunction in women desiring pregnancy [7]. Its label has no male indication and says there are no adequate or well-controlled studies demonstrating effectiveness in male infertility; testicular tumors and gynecomastia have been reported in males using clomiphene, with cause and effect not known [7]. Male use of clomiphene for low testosterone is off-label [7]. Enclomiphene is not interchangeable with clomiphene.

A retrospective study of 66 men who took clomiphene and later enclomiphene found a median testosterone rise of 166 versus 98 ng/dL (P=0.20) and an estradiol change of -5.92 versus +17.50 pg/mL (P=0.001); side effects were less frequent on enclomiphene (odds ratio 0.18, 95% CI 0.07 to 0.44) [8]. That study was retrospective, not randomized.

Pharmacokinetics: how long the drug stays active

Oral enclomiphene is absorbed rapidly, with a peak 2 to 3 hours after a dose and a half-life of about 10 hours [1]. Its main metabolite is 4-hydroxy enclomiphene, and excretion is mainly in the feces [1]. There is no FDA-approved dose because there is no approved product [1]. A phase 2 dose-finding trial studied 6.25, 12.5 and 25 mg once daily for 6 weeks [9]. Phase 3 protocols used 12.5 mg once daily, with up-titration to 25 mg daily at week 6 if morning testosterone stayed below 300 ng/dL [4].

What are the safety concerns?

FDA listed cardiac and thromboembolic events, including pulmonary embolism and deep vein thrombosis in a safety study, raised estradiol, raised PSA, raised hematocrit and no long-term safety data [1]. EMA noted a slightly higher rate of cardiac and thromboembolic events than with testosterone; cataracts were seen in nonclinical studies and EMA wanted ocular monitoring [1]. In phase 3 and EMA data, the most frequent side effects were headache, hot flushes, nausea and muscle spasm; reasons for stopping included blurred vision, muscle spasm, headache and aggression [5]. In ZA-302, headache was 7 of 112 on 12.5 mg versus 1 of 47 on placebo; nausea was 4 of 112 versus 3 of 47 [5].

The clomiphene label warns about visual symptoms such as blurring, scotomata and flashes, which are usually reversible but may rarely persist [7]. That warning is for the mixture, not proven for enclomiphene alone.

Regulatory status and compounding

Enclomiphene is not FDA-approved. FDA's June 8, 2022 advisory-committee presentation says no FDA-approved drugs contain enclomiphene as an active ingredient [1]. In 2015, FDA sent the sponsor a complete response letter for Androxal, and no FDA approval has followed [1]. EMA's CHMP adopted a negative opinion on 25 January 2018 recommending refusal of marketing authorisation for EnCyzix for hypogonadotropic hypogonadism in overweight men with BMI at least 25, based on 4 main studies in 588 patients [2].

Enclomiphene is not on FDA's final list of bulk substances that can be used in compounding; it is in Category 1, bulk drug substances under evaluation, in a list updated May 14, 2026 [10]. FDA says it does not intend to take action against a compounder using a Category 1 substance if the conditions in its guidance are met; that is enforcement discretion, not approval and not a finding that the product is safe or effective [10]. At the June 8, 2022 advisory committee, FDA proposed that enclomiphene citrate not be added to the allowed bulk substances list; the vote was Yes 4, No 8, Abstain 0 [11].

Where the evidence stands

The BSSM 2026 position statement calls enclomiphene promising for men with secondary hypogonadism who want to preserve fertility, but notes the evidence is from small short-term studies and does not recommend routine use outside specialist settings [6].

Frequently asked questions

›What is the mechanism of enclomiphene citrate?

Enclomiphene is an oral selective estrogen receptor modulator. It blocks estrogen receptors in the pituitary, so the pituitary releases more LH and FSH. LH signals Leydig cells in the testes to make testosterone, and FSH supports Sertoli cells and sperm production [1].

›How is enclomiphene different from clomiphene?

Clomiphene is a mixture of enclomiphene (trans) and zuclomiphene (cis); the USP monograph gives enclomiphene content of clomiphene as 50 to 70 percent [1]. Zuclomiphene is more estrogenic, and the clomiphene label says zuclomiphene has a longer half-life, with detectable levels persisting for longer than a month [7][6]. Enclomiphene is not FDA-approved; clomiphene is approved for ovulatory dysfunction in women [1][7].

›Does enclomiphene raise sperm count?

It raises LH and FSH, which the testes need for sperm production, but the sperm response varies. In two phase 3 studies, sperm concentration stayed in the normal range on enclomiphene while testosterone gel caused a marked reduction in spermatogenesis [3]. Sperm concentration fell by 50% or more in 14.2% of men on enclomiphene versus 2.6% on placebo in ZA-301, and 14.2% versus 4.3% in ZA-302 [4][5].

›Does enclomiphene raise estrogen?

Estradiol can rise: raised estradiol was one of the safety concerns FDA listed in 2022 [1]. In a retrospective study of 66 men, estradiol changed by -5.92 pg/mL with enclomiphene versus +17.50 pg/mL with clomiphene [8].

›Does enclomiphene work for primary hypogonadism?

No. Enclomiphene works by raising LH and FSH so the testes make more testosterone. In primary hypogonadism, testicular failure prevents the testes from responding adequately to that signal, so the mechanism would not be expected to work [1].

References

1. U.S. Food and Drug Administration. U.S. Food and Drug Administration
2. Official web page. Official web page
3. Kim ED, McCullough A, Kaminetsky J. Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone: restoration instead of replacement. BJU Int. 2016;117(4):677-85. Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone: restoration instead of replacement
4. Official web page. Official web page
5. Official web page. Official web page
6. Foster J, Choo L, Patel A, Kirby M, Hackett G. British Society of Sexual Medicine: Position Statement for the Potential Use of Enclomiphene in the Treatment of Male Hypogonadism. World J Mens Health. 2026;44(3):480-483. British Society of Sexual Medicine: Position Statement for the Potential Use of Enclomiphene in the Treatment of Male Hypogonadism
7. U.S. National Library of Medicine, DailyMed. Clomid (clomiphene citrate) tablets, Cosette prescribing information. Clomid (clomiphene citrate) tablets, Cosette label
8. Saffati G, Kassab J, Orozco Rendon D, Hinojosa-Gonzalez DE, Kronstedt S, Lipshultz LI, et al. Safety and efficacy of enclomiphene and clomiphene for hypogonadal men. Transl Androl Urol. 2024;13(9):1984-1990. Safety and efficacy of enclomiphene and clomiphene for hypogonadal men
9. Wiehle R, Cunningham GR, Pitteloud N, Wike J, Hsu K, Fontenot GK, et al. Testosterone Restoration by Enclomiphene Citrate in Men with Secondary Hypogonadism: Pharmacodynamics and Pharmacokinetics. BJU Int. 2013;112(8):1188-200. Testosterone Restoration by Enclomiphene Citrate in Men with Secondary Hypogonadism: Pharmacodynamics and Pharmacokinetics
10. U.S. Food and Drug Administration. U.S. Food and Drug Administration
11. U.S. Food and Drug Administration. U.S. Food and Drug Administration